Bayer Aims For Global Analgesic Market Dominance With Aleve, Aspirin
This article was originally published in The Tan Sheet
Executive Summary
The consolidation of the Aleve (naproxen sodium) franchise under one roof - and its pairing with Bayer Aspirin - appears to be a primary driver of Bayer's acquisition of Roche Consumer Health
You may also be interested in...
Xenical Rx-To-OTC Switch In The Works, GSK/Roche Announce
Roche and GlaxoSmithKline appear to be moving quickly on an Rx-to-OTC switch application for the anti-obesity agent Xenical (orlistat)
Bayer/Roche Consumer Unit Will Focus On Rx-To-OTC Switch Opportunities
Bayer expects the addition of Roche Consumer Health to bolster the firm's ability to handle future Rx-to-OTC switches
Xenical Rx-To-OTC Switch In The Works, GSK/Roche Announce
Roche and GlaxoSmithKline appear to be moving quickly on an Rx-to-OTC switch application for the anti-obesity agent Xenical (orlistat)